Magneziumterapia akut szivinfarktusban

Translated title of the contribution: Magnesium therapy in acute myocardial infarction

Research output: Contribution to journalArticle

Abstract

The value of intravenous magnesium treatment in patients with acute myocardial infarction is controversial. Magnesium therapy reduced the mortality in animal studies and in ten smaller clinical trials. The beneficial effect was due to the reduced infarct size and the limitation of reperfusion injuries. Magnesium may protect myocytes via several mechanisms: (1) reduced vulnerability to oxygen-derived free radicals, (2) decreased cytosolic calcium levels by inhibition of inward flux of calcium ions, (3) reduced myocardial oxygen demand via sinus slowing and lowering of blood pressure, (4) coronary vasodilatation and enhancement of collateral development, and (5) inhibition of platelet aggregation. Magnesium decreased the myocardial necrosis and reduced the mortality only in those studies when it was administered in the early phase of the acute myocardial infarction, before or within a very short interval after reperfusion achieved either spontaneous or via thrombolysis. Mortality reduction with magnesium was the greatest in patients with the highest baseline risk. There was a considerable benefit of magnesium treatment in the elderly and in patients who were not candidates for thrombolytic therapy. In contrast to several smaller studies, however the magnesium sulphate did not decrease the mortality of patients with acute myocardial infarction in a large, international randomized trial of 58 050 patients (ISIS-4). The inefficiency of magnesium treatment in ISIS- 4 may have been due to the late administration of magnesium to inherently lowrisk patients. In patients receiving thrombolytic therapy magnesium infusions were delayed 1 to 2 hours after the fibrinolytic treatment in ISIS- 4. The time of magnesium administration is probably critical in order to achieve the benefit of this treatment. Magnesium may decrease myocardial damage and reduces mortality if it is administered before reperfusion occurs.

Original languageHungarian
Pages (from-to)612-617
Number of pages6
JournalLege Artis Medicinae
Volume6
Issue number11
Publication statusPublished - 1996

Fingerprint

Magnesium
Myocardial Infarction
Mortality
Therapeutics
Thrombolytic Therapy
Reperfusion
Oxygen
Calcium
Magnesium Sulfate
Reperfusion Injury
Platelet Aggregation
Vasodilation
Muscle Cells
Free Radicals
Necrosis
Clinical Trials
Ions
Blood Pressure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Magneziumterapia akut szivinfarktusban. / Hosszúfalusi, N.; Kempler, P.

In: Lege Artis Medicinae, Vol. 6, No. 11, 1996, p. 612-617.

Research output: Contribution to journalArticle

@article{3e0ea36e6ab545f09b918cc13fd0872b,
title = "Magneziumterapia akut szivinfarktusban",
abstract = "The value of intravenous magnesium treatment in patients with acute myocardial infarction is controversial. Magnesium therapy reduced the mortality in animal studies and in ten smaller clinical trials. The beneficial effect was due to the reduced infarct size and the limitation of reperfusion injuries. Magnesium may protect myocytes via several mechanisms: (1) reduced vulnerability to oxygen-derived free radicals, (2) decreased cytosolic calcium levels by inhibition of inward flux of calcium ions, (3) reduced myocardial oxygen demand via sinus slowing and lowering of blood pressure, (4) coronary vasodilatation and enhancement of collateral development, and (5) inhibition of platelet aggregation. Magnesium decreased the myocardial necrosis and reduced the mortality only in those studies when it was administered in the early phase of the acute myocardial infarction, before or within a very short interval after reperfusion achieved either spontaneous or via thrombolysis. Mortality reduction with magnesium was the greatest in patients with the highest baseline risk. There was a considerable benefit of magnesium treatment in the elderly and in patients who were not candidates for thrombolytic therapy. In contrast to several smaller studies, however the magnesium sulphate did not decrease the mortality of patients with acute myocardial infarction in a large, international randomized trial of 58 050 patients (ISIS-4). The inefficiency of magnesium treatment in ISIS- 4 may have been due to the late administration of magnesium to inherently lowrisk patients. In patients receiving thrombolytic therapy magnesium infusions were delayed 1 to 2 hours after the fibrinolytic treatment in ISIS- 4. The time of magnesium administration is probably critical in order to achieve the benefit of this treatment. Magnesium may decrease myocardial damage and reduces mortality if it is administered before reperfusion occurs.",
keywords = "Drug therapy of myocardial infarction, Myocardial necrosis, Reperfusion injury, Therapeutic use of magnesium",
author = "N. Hossz{\'u}falusi and P. Kempler",
year = "1996",
language = "Hungarian",
volume = "6",
pages = "612--617",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "11",

}

TY - JOUR

T1 - Magneziumterapia akut szivinfarktusban

AU - Hosszúfalusi, N.

AU - Kempler, P.

PY - 1996

Y1 - 1996

N2 - The value of intravenous magnesium treatment in patients with acute myocardial infarction is controversial. Magnesium therapy reduced the mortality in animal studies and in ten smaller clinical trials. The beneficial effect was due to the reduced infarct size and the limitation of reperfusion injuries. Magnesium may protect myocytes via several mechanisms: (1) reduced vulnerability to oxygen-derived free radicals, (2) decreased cytosolic calcium levels by inhibition of inward flux of calcium ions, (3) reduced myocardial oxygen demand via sinus slowing and lowering of blood pressure, (4) coronary vasodilatation and enhancement of collateral development, and (5) inhibition of platelet aggregation. Magnesium decreased the myocardial necrosis and reduced the mortality only in those studies when it was administered in the early phase of the acute myocardial infarction, before or within a very short interval after reperfusion achieved either spontaneous or via thrombolysis. Mortality reduction with magnesium was the greatest in patients with the highest baseline risk. There was a considerable benefit of magnesium treatment in the elderly and in patients who were not candidates for thrombolytic therapy. In contrast to several smaller studies, however the magnesium sulphate did not decrease the mortality of patients with acute myocardial infarction in a large, international randomized trial of 58 050 patients (ISIS-4). The inefficiency of magnesium treatment in ISIS- 4 may have been due to the late administration of magnesium to inherently lowrisk patients. In patients receiving thrombolytic therapy magnesium infusions were delayed 1 to 2 hours after the fibrinolytic treatment in ISIS- 4. The time of magnesium administration is probably critical in order to achieve the benefit of this treatment. Magnesium may decrease myocardial damage and reduces mortality if it is administered before reperfusion occurs.

AB - The value of intravenous magnesium treatment in patients with acute myocardial infarction is controversial. Magnesium therapy reduced the mortality in animal studies and in ten smaller clinical trials. The beneficial effect was due to the reduced infarct size and the limitation of reperfusion injuries. Magnesium may protect myocytes via several mechanisms: (1) reduced vulnerability to oxygen-derived free radicals, (2) decreased cytosolic calcium levels by inhibition of inward flux of calcium ions, (3) reduced myocardial oxygen demand via sinus slowing and lowering of blood pressure, (4) coronary vasodilatation and enhancement of collateral development, and (5) inhibition of platelet aggregation. Magnesium decreased the myocardial necrosis and reduced the mortality only in those studies when it was administered in the early phase of the acute myocardial infarction, before or within a very short interval after reperfusion achieved either spontaneous or via thrombolysis. Mortality reduction with magnesium was the greatest in patients with the highest baseline risk. There was a considerable benefit of magnesium treatment in the elderly and in patients who were not candidates for thrombolytic therapy. In contrast to several smaller studies, however the magnesium sulphate did not decrease the mortality of patients with acute myocardial infarction in a large, international randomized trial of 58 050 patients (ISIS-4). The inefficiency of magnesium treatment in ISIS- 4 may have been due to the late administration of magnesium to inherently lowrisk patients. In patients receiving thrombolytic therapy magnesium infusions were delayed 1 to 2 hours after the fibrinolytic treatment in ISIS- 4. The time of magnesium administration is probably critical in order to achieve the benefit of this treatment. Magnesium may decrease myocardial damage and reduces mortality if it is administered before reperfusion occurs.

KW - Drug therapy of myocardial infarction

KW - Myocardial necrosis

KW - Reperfusion injury

KW - Therapeutic use of magnesium

UR - http://www.scopus.com/inward/record.url?scp=0030429748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030429748&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 612

EP - 617

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 11

ER -